Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin

Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin (2004)

Authors:
Autor USP: FORTI, NEUSA ASSUMPTA - FM
Unidade: FM
Subjects: MUTAÇÃO GENÉTICA; HIPERCOLESTEROLEMIA; CORONARIOPATIA (PREVENÇÃO E CONTROLE)
Language: Inglês
Imprenta:
- Publisher place: Amsterdam
- Date published: 2004
Source:
- Título do periódico: Atherosclerosis
- Volume/Número/Paginação/Ano: v. 5, n. 1, p. 112, res. M.484, 2004
Conference titles: Congress of the European Atherosclerosis Society

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

ABNT

CAVALI, S. et al. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 16 abr. 2024. , 2004
APA

Cavali, S., Moretti, I., Matsumoto, L., Salazar, L., Hiroyuki, M., Forti, N. A., et al. (2004). Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. Amsterdam: Faculdade de Medicina, Universidade de São Paulo.
NLM

Cavali S, Moretti I, Matsumoto L, Salazar L, Hiroyuki M, Forti NA, Diament J, Chiara M, Faludi A, Dominguez R. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. 2004 ; 5( 1): 112.[citado 2024 abr. 16 ]
Vancouver

Cavali S, Moretti I, Matsumoto L, Salazar L, Hiroyuki M, Forti NA, Diament J, Chiara M, Faludi A, Dominguez R. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. 2004 ; 5( 1): 112.[citado 2024 abr. 16 ]